Ra Capital Management, L.P. Purchases 391,019 Shares of Artiva Biotherapeutics (NASDAQ:ARTV) Stock

Posted by Brian Himes on Jun 16th, 2026

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV – Get Free Report) Director Ra Capital Management, L.P. bought 391,019 shares of the stock in a transaction dated Friday, June 12th. The shares were bought at an average cost of $8.57 per share, with a total value of $3,351,032.83. Following the completion of the acquisition, the director directly owned 16,622,736 shares of the company’s stock, valued at approximately $142,456,847.52. The trade was a 2.41% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Ra Capital Management, L.P. also recently made the following trade(s):

On Tuesday, June 16th, Ra Capital Management, L.P. bought 124,893 shares of Artiva Biotherapeutics stock. The shares were bought at an average cost of $8.89 per share, with a total value of $1,110,298.77.
On Monday, June 15th, Ra Capital Management, L.P. bought 15,414 shares of Artiva Biotherapeutics stock. The shares were bought at an average cost of $8.99 per share, with a total value of $138,571.86.
On Thursday, June 11th, Ra Capital Management, L.P. bought 548,580 shares of Artiva Biotherapeutics stock. The shares were bought at an average cost of $7.91 per share, with a total value of $4,339,267.80.
On Wednesday, June 10th, Ra Capital Management, L.P. bought 103 shares of Artiva Biotherapeutics stock. The shares were bought at an average cost of $7.00 per share, with a total value of $721.00.
On Tuesday, June 9th, Ra Capital Management, L.P. bought 479,039 shares of Artiva Biotherapeutics stock. The shares were bought at an average cost of $6.91 per share, with a total value of $3,310,159.49.
On Monday, May 11th, Ra Capital Management, L.P. bought 6,510,416 shares of Artiva Biotherapeutics stock. The shares were bought at an average cost of $11.52 per share, with a total value of $74,999,992.32.

Artiva Biotherapeutics Stock Down 2.9%

Shares of NASDAQ:ARTV traded down $0.27 during trading on Tuesday, hitting $8.91. 780,946 shares of the company traded hands, compared to its average volume of 355,699. The stock has a market capitalization of $220.26 million, a price-to-earnings ratio of -2.52 and a beta of 2.40. The business’s fifty day moving average is $8.98 and its 200-day moving average is $6.20. Artiva Biotherapeutics, Inc. has a one year low of $1.47 and a one year high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV – Get Free Report) last posted its earnings results on Friday, May 8th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.07). On average, analysts forecast that Artiva Biotherapeutics, Inc. will post -2.45 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on ARTV. Needham & Company LLC reissued a “buy” rating and issued a $41.00 price objective on shares of Artiva Biotherapeutics in a report on Monday, June 8th. Wedbush increased their price objective on Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an “outperform” rating in a report on Monday, May 11th. Wall Street Zen lowered Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a report on Sunday, May 17th. Cantor Fitzgerald reissued an “overweight” rating on shares of Artiva Biotherapeutics in a report on Tuesday, May 26th. Finally, HC Wainwright increased their price objective on Artiva Biotherapeutics from $15.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Artiva Biotherapeutics currently has an average rating of “Moderate Buy” and an average target price of $39.00.

Check Out Our Latest Report on Artiva Biotherapeutics

Hedge Funds Weigh In On Artiva Biotherapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ARTV. Citadel Advisors LLC grew its holdings in Artiva Biotherapeutics by 419.3% in the 3rd quarter. Citadel Advisors LLC now owns 798,397 shares of the company’s stock worth $2,291,000 after buying an additional 644,658 shares in the last quarter. BNP Paribas Financial Markets grew its holdings in Artiva Biotherapeutics by 14,463.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock worth $340,000 after buying an additional 117,733 shares in the last quarter. Marshall Wace LLP acquired a new stake in Artiva Biotherapeutics in the fourth quarter worth approximately $341,000. Jane Street Group LLC acquired a new stake in Artiva Biotherapeutics in the second quarter worth approximately $67,000. Finally, Landscape Capital Management L.L.C. acquired a new stake in Artiva Biotherapeutics in the third quarter worth approximately $112,000.

Artiva Biotherapeutics Company Profile

(Get Free Report)

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.